Travere Therapeutics, Inc.
General ticker "TVTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.7B (TTM average)
Travere Therapeutics, Inc. follows the US Stock Market performance with the rate: 50.0%.
Estimated limits based on current volatility of 2.3%: low 34.12$, high 35.47$
Factors to consider:
- Total employees count: 385 as of 2024
- Top business risk factors: Commercialization challenges, Sales and marketing challenges, Limited operating history, Operational and conduct risks, Licensing risks
- Current price 41.3% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [10.49$, 25.00$]
- 2025-12-31 to 2026-12-31 estimated range: [8.28$, 20.20$]
Financial Metrics affecting the TVTX estimates:
- Negative: with PPE of -4.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -17.42 <= 0.33
- Positive: Investing cash flow per share per price, % of 7.29 > -0.66
- Negative: Shareholder equity ratio, % of 9.94 <= 18.93
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0.82 <= 3.41
Short-term TVTX quotes
Long-term TVTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $109.46MM | $145.24MM | $233.18MM |
| Operating Expenses | $429.27MM | $533.38MM | $557.00MM |
| Operating Income | $-319.81MM | $-388.14MM | $-323.83MM |
| Non-Operating Income | $-11.34MM | $12.03MM | $3.32MM |
| Interest Expense | $11.01MM | $11.33MM | $11.18MM |
| R&D Expense | $227.33MM | $244.99MM | $282.70MM |
| Income(Loss) | $-331.15MM | $-376.11MM | $-320.51MM |
| Taxes | $0.31MM | $0.22MM | $0.12MM |
| Other Income(Loss) | $52.99MM | $264.93MM | $-0.92MM |
| Profit(Loss)* | $-278.48MM | $-111.40MM | $-322.46MM |
| Stockholders Equity | $42.85MM | $200.81MM | $59.08MM |
| Inventory | $4.52MM | $9.41MM | $6.20MM |
| Assets | $672.59MM | $788.91MM | $594.12MM |
| Operating Cash Flow | $-186.29MM | $-280.02MM | $-237.47MM |
| Capital expenditure | $28.37MM | $41.59MM | $101.21MM |
| Investing Cash Flow | $-32.55MM | $55.78MM | $99.33MM |
| Financing Cash Flow | $117.57MM | $218.75MM | $139.42MM |
| Earnings Per Share** | $-4.37 | $-1.50 | $-4.09 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.